Anteris Technologies has enrolled and treated the first U.S. patients in its global PARADIGM trial, testing the DurAVR Transcatheter Heart Valve for severe aortic stenosis. This randomized trial compares DurAVR to existing TAVR devices, aiming to prove safety and effectiveness in about 1,000 patients. The trial's results will help guide future treatment decisions for aortic valve disease. The U.S. enrollment marks a key milestone following CMS reimbursement approval, expanding the trial's reach and recruitment potential.
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
DeFi platform Aave introduced Stable Vaults, enabling fintechs and payment providers to offer fixed-rate stablecoin yields, enhancing its ecosystem. This launch, alongside the Aave V4 upgrade, increased token trading volume by 14.5% and price by near...
Morgan Stanley has filed to launch Ethereum and Solana ETFs with a competitive 0.14% management fee, aiming to capture market share as crypto ETFs become more commoditized. These ETFs will offer direct token exposure, staking rewards, and institution...
